Observational studyBritish journal of clinical pharmacology2017

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Christopher Vinnard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.